What could explain the discordant results between PARP/abiraterone combinations in MAGNITUDE and PROpel in non-HRRm prostate cancer?

Do the contradictory results of PROPEL and MAGNITUDE trials raise concerns about the efficacy of PARP inhibition in CRPC?

• Yes, as a result I don't use PARP inhibitors for any patients with CRPC
• Yes, as a result I only use PARP inhibitors for patients with HRD-mutated CRPC
• No concerns, I would use PARP inhibitors in all patients with CRPC
• No concerns, but I restrict PARP inhibitors to HRD+ CRPC for other reasons
• No concerns, but I don't plan to use PARP inhibitors for CRPC for other reasons
• Other